Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ENERGI-F711 is a topical burn cream developed for the treatment of skin injuries, specifically targeting second-degree burns and scalds. Preclinical studies in animal models (pigs) have demonstrated that ENERGI-F711 can curb inflammation and accelerate wound healing in serious second-degree burns. The product is being developed by Energenesis Biomedical, a company focused on innovative therapies for skin diseases and wound care. While detailed molecular mechanisms are not disclosed publicly, the product's primary action appears to be anti-inflammatory and pro-healing at the site of injury[1][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ENERGI-F711.